rheumatology
Gout

Rhabdomyolysis risk from febuxostat

A combination of chronic kidney disease and statin therapy may represent a risk for the rare side-effect of rhabdomyolysis in patients treated with febuxostat for gout, a case report from St Vincent’s Hospital in Sydney suggests. Dr Debasish Ghosh and colleagues, writing in the MJA, described a 68 year old man with stage 3 CKD ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic